BACKGROUND: Even in castration-resistant prostate cancer (CRPC), the androgen pathway remains biologically relevant. In preclinical models, androgen therapy for CRPC leads to growth arrest, apoptosis, and tumor shrinkage. OBJECTIVE: This study sought to determine the toxicity and feasibility of a testosterone therapy in early CRPC. DESIGN, SETTING, AND PARTICIPANTS: Prostate cancer patients with progressive disease following androgen ablation, antiandrogen therapy, and withdrawal and no to minimal metastatic disease who were followed at the University of Chicago were randomized to treatment with three doses of transdermal testosterone. INTERVENTION: Patients were treated with transdermal testosterone at 2.5, 5.0, or 7.5 mg/day. MEASUREMENTS: Toxicity, prostate-specific antigen (PSA), imaging, quality of life (QoL), and strength were monitored. Treatment was discontinued for significant toxicity, clinical progression, or a 3-fold increase in PSA. RESULTS AND LIMITATIONS: Fifteen men with a median age of 73 yr (range: 62-92) and a median PSA of 11.1 ng/ml (range: 5.2-63.6) were treated. Testosterone increased from castrate to median concentrations of 305 ng/dl, 308 ng/dl, and 297 ng/dl for dosages of 2.5 mg/day (n=4), 5.0 mg/day (n=5), and 7.5 mg/day (n=5), respectively. One patient was taken off of the study at 53 wk due to grade 4 cardiac toxicity. There were no other grade 3 or 4 toxicities related to the study medication, and the grade 2 toxicities were minimal. Only one patient experienced symptomatic progression, and three (20%) patients demonstrated a decrease in PSA (largest was 43%). Median time to progression was 9 wk (range: 2-96), with no detectable difference in the three dose cohorts. There was no significant improvement in QoL, and there was a borderline statistically significant improvement in hand-grip strength with treatment. The study was limited by sample size, single arm, and variability of baseline patient characteristics. CONCLUSIONS:Testosterone is a feasible and reasonably well-tolerated therapy for men with early CRPC. A larger, randomized trial is under way to further characterize efficacy and impact on QoL measures.
RCT Entities:
BACKGROUND: Even in castration-resistant prostate cancer (CRPC), the androgen pathway remains biologically relevant. In preclinical models, androgen therapy for CRPC leads to growth arrest, apoptosis, and tumor shrinkage. OBJECTIVE: This study sought to determine the toxicity and feasibility of a testosterone therapy in early CRPC. DESIGN, SETTING, AND PARTICIPANTS: Prostate cancerpatients with progressive disease following androgen ablation, antiandrogen therapy, and withdrawal and no to minimal metastatic disease who were followed at the University of Chicago were randomized to treatment with three doses of transdermal testosterone. INTERVENTION: Patients were treated with transdermal testosterone at 2.5, 5.0, or 7.5 mg/day. MEASUREMENTS: Toxicity, prostate-specific antigen (PSA), imaging, quality of life (QoL), and strength were monitored. Treatment was discontinued for significant toxicity, clinical progression, or a 3-fold increase in PSA. RESULTS AND LIMITATIONS: Fifteen men with a median age of 73 yr (range: 62-92) and a median PSA of 11.1 ng/ml (range: 5.2-63.6) were treated. Testosterone increased from castrate to median concentrations of 305 ng/dl, 308 ng/dl, and 297 ng/dl for dosages of 2.5 mg/day (n=4), 5.0 mg/day (n=5), and 7.5 mg/day (n=5), respectively. One patient was taken off of the study at 53 wk due to grade 4 cardiac toxicity. There were no other grade 3 or 4 toxicities related to the study medication, and the grade 2 toxicities were minimal. Only one patient experienced symptomatic progression, and three (20%) patients demonstrated a decrease in PSA (largest was 43%). Median time to progression was 9 wk (range: 2-96), with no detectable difference in the three dose cohorts. There was no significant improvement in QoL, and there was a borderline statistically significant improvement in hand-grip strength with treatment. The study was limited by sample size, single arm, and variability of baseline patient characteristics. CONCLUSIONS:Testosterone is a feasible and reasonably well-tolerated therapy for men with early CRPC. A larger, randomized trial is under way to further characterize efficacy and impact on QoL measures.
Authors: James Mohler; Richard J Babaian; Robert R Bahnson; Barry Boston; Anthony D'Amico; James A Eastham; Ralph J Hauke; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Chris Logothetis; Gary MacVicar; Alan Pollack; Julio M Pow-Sang; Mack Roach; Howard Sandler; Dennis Shrieve; Sandhya Srinivas; Przemyslaw Twardowski; Donald A Urban; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2007-08 Impact factor: 11.908
Authors: D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: Marielle H Emmelot-Vonk; Harald J J Verhaar; Hamid R Nakhai Pour; André Aleman; Tycho M T W Lock; J L H Ruud Bosch; Diederick E Grobbee; Yvonne T van der Schouw Journal: JAMA Date: 2008-01-02 Impact factor: 56.272
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Henry K Tsai; Anthony V D'Amico; Natalia Sadetsky; Ming-Hui Chen; Peter R Carroll Journal: J Natl Cancer Inst Date: 2007-10-09 Impact factor: 13.506
Authors: Christopher S Saigal; John L Gore; Tracey L Krupski; Janet Hanley; Matthias Schonlau; Mark S Litwin Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff Journal: J Clin Oncol Date: 2007-06-10 Impact factor: 44.544
Authors: Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade Journal: Sci Transl Med Date: 2015-01-07 Impact factor: 17.956
Authors: Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson Journal: J Clin Invest Date: 2019-07-16 Impact factor: 14.808
Authors: Nicole A Traphagen; Sarah R Hosford; Amanda Jiang; Jonathan D Marotti; Brooke L Brauer; Eugene Demidenko; Todd W Miller Journal: Oncogene Date: 2021-04-19 Impact factor: 9.867